12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Stromal tumor-infiltrating lymphocytes (TILs) are a robust prognostic factor in triple-negative breast cancer (TNBC). However, the clinical significance of TILs may be influenced by the complex landscape of the tumor immune microenvironment. In this study, we aimed to evaluate the composition and the functionality of lymphocytic infiltration and checkpoint receptors in TNBC.

          Methods

          Formalin-fixed, paraffin-embedded tissues were retrospectively collected from a cohort of patients with early-stage TNBC treated with adjuvant anthracycline-based chemotherapy (n = 259). Results were validated in an independent cohort of patients with TNBC (n = 104). Stromal TILs were evaluated on hematoxylin-and-eosin-stained sections. The density of CD4+, CD8+, and FOXP3+ lymphocytes, and the expression of the immune checkpoints PD-1 and LAG-3, were assessed by immunohistochemical analysis.

          Results

          The presence of elevated TILs positively correlated with the density of all T cell subtypes, especially cytotoxic CD8+ lymphocytes. We showed that increasing stromal TILs assessed as a continuous variable is an independent prognostic marker of prolonged relapse-free survival and overall survival in TNBC. Among immune subpopulations, CD8+ lymphocytes are the main effectors of anti-tumor immune responses. In two independent cohorts, we found that PD-1 and LAG-3 were concurrently expressed in approximately 15% of patients with TNBC. The expression of both checkpoint receptors positively correlated with the presence of TILs, but was not significantly associated with patient outcome.

          Conclusions

          Overall, our data indicate that the evaluation of stromal TILs remains the most reliable immune prognostic marker in TNBC, and support the clinical evaluation of anti-PD-1/PD-L1 and anti-LAG-3 in a subset of patients with TNBC who have concurrent expression of both checkpoint receptors.

          Electronic supplementary material

          The online version of this article (doi:10.1186/s13058-016-0783-4) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references14

          • Record: found
          • Abstract: found
          • Article: not found

          Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

          Recent studies suggest that tumor-infiltrating lymphocytes (TILs) are associated with disease-free (DFS) and overall survival (OS) in operable triple-negative breast cancer (TNBC). We seek to validate the prognostic impact of TILs in primary TNBCs in two adjuvant phase III trials conducted by the Eastern Cooperative Oncology Group (ECOG). Full-face hematoxylin and eosin–stained sections of 506 tumors from ECOG trials E2197 and E1199 were evaluated for density of TILs in intraepithelial (iTILs) and stromal compartments (sTILs). Patient cases of TNBC from E2197 and E1199 were randomly selected based on availability of sections. For the primary end point of DFS, association with TIL scores was determined by fitting proportional hazards models stratified on study. Secondary end points were OS and distant recurrence–free interval (DRFI). Reporting recommendations for tumor marker prognostic studies criteria were followed, and all analyses were prespecified. The majority of 481 evaluable cancers had TILs (sTILs, 80%; iTILs, 15%). With a median follow-up of 10.6 years, higher sTIL scores were associated with better prognosis; for every 10% increase in sTILs, a 14% reduction of risk of recurrence or death (P = .02), 18% reduction of risk of distant recurrence (P = .04), and 19% reduction of risk of death (P = .01) were observed. Multivariable analysis confirmed sTILs to be an independent prognostic marker of DFS, DRFI, and OS. In two national randomized clinical trials using contemporary adjuvant chemotherapy, we confirm that stromal lymphocytic infiltration constitutes a robust prognostic factor in TNBCs. Studies assessing outcomes and therapeutic efficacies should consider stratification for this parameter.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

            Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 (HER2) -positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) and immunologically relevant genes in the neoadjuvant GeparSixto trial.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

              T-cell infiltration in estrogen receptor (ER)-negative breast tumours has been associated with longer survival. To investigate this association and the potential of tumour T-cell infiltration as a prognostic and predictive marker, we have conducted the largest study of T cells in breast cancer to date.
                Bookmark

                Author and article information

                Contributors
                giulia.bottai@hotmail.com
                carlotta.raschioni@humanitas.it
                agnese.losurdo@cancercenter.humanitas.it
                luca.di_tommaso@hunimed.eu
                corrado.tinterri@cancercenter.humanitas.it
                rosalba.torrisi@cancercenter.humanitas.it
                reisfilj@mskcc.org
                massimo_guglielmo.roncalli@humanitas.it
                christos.sotiriou@bordet.be
                armando.santoro@cancercenter.humanitas.it
                alberto.mantovani@humanitasresearch.it , alberto.mantovani@hunimed.eu
                sherene.loi@petermac.org
                +39 02 8224 5173 , liberosantarpia@yahoo.it , libero.santarpia@humanitasresearch.it
                Journal
                Breast Cancer Res
                Breast Cancer Res
                Breast Cancer Research : BCR
                BioMed Central (London )
                1465-5411
                1465-542X
                3 December 2016
                3 December 2016
                2016
                : 18
                : 121
                Affiliations
                [1 ]Oncology Experimental Therapeutics, IRCCS Clinical and Research Institute Humanitas, Via Manzoni 113, 20089 Rozzano-Milan, Italy
                [2 ]Department of Oncology, IRCCS Clinical and Research Institute Humanitas, Rozzano-Milan, Italy
                [3 ]Department of Pathology, IRCCS Clinical and Research Institute Humanitas, Rozzano-Milan, Italy
                [4 ]Department of Surgery, IRCCS Clinical and Research Institute Humanitas, Rozzano-Milan, Italy
                [5 ]Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA
                [6 ]Humanitas University, Rozzano-Milan, Italy
                [7 ]Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
                [8 ]Department of Immunology and Inflammation, IRCCS Clinical and Research Institute Humanitas, Rozzano-Milan, Italy
                [9 ]Division of Cancer Medicine and Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria Australia
                Article
                783
                10.1186/s13058-016-0783-4
                5135782
                27912781
                10787313-c889-4738-a6a8-0d69c3311893
                © The Author(s). 2016

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 28 April 2016
                : 22 November 2016
                Funding
                Funded by: from Associazione Italiana Ricerca sul Cancro
                Award ID: AIRC Grant 6251
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100007076, Fondazione Italiana per la Ricerca sul Cancro;
                Award ID: 18328
                Award Recipient :
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2016

                Oncology & Radiotherapy
                immune checkpoints,lag-3,prognosis,triple-negative breast cancer,tumor-infiltrating lymphocytes

                Comments

                Comment on this article